ACADIA Pharmaceuticals/$ACAD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Ticker
$ACAD
Sector
Primary listing
Employees
654
Headquarters
Website
ACAD Metrics
BasicAdvanced
$3.4B
15.13
$1.33
0.71
-
Price and volume
Market cap
$3.4B
Beta
0.71
52-week high
$26.65
52-week low
$13.40
Average daily volume
2.2M
Financial strength
Current ratio
2.911
Quick ratio
2.672
Long term debt to equity
5.423
Total debt to equity
6.845
Profitability
EBITDA (TTM)
103.965
Gross margin (TTM)
60.22%
Net profit margin (TTM)
21.80%
Operating margin (TTM)
8.86%
Effective tax rate (TTM)
17.07%
Revenue per employee (TTM)
$1,560,000
Management effectiveness
Return on assets (TTM)
5.28%
Return on equity (TTM)
33.18%
Valuation
Price to earnings (TTM)
15.132
Price to revenue (TTM)
3.284
Price to book
4.09
Price to tangible book (TTM)
4.78
Price to free cash flow (TTM)
37.914
Free cash flow yield (TTM)
2.64%
Free cash flow per share (TTM)
0.529
Growth
Revenue change (TTM)
14.41%
Earnings per share change (TTM)
615.00%
3-year revenue growth (CAGR)
25.75%
10-year revenue growth (CAGR)
161.94%
3-year earnings per share growth (CAGR)
1.44%
10-year earnings per share growth (CAGR)
-0.09%
What the Analysts think about ACAD
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
Bulls say / Bears say
A U.S. Court of Appeals confirmed the validity of NUPLAZID’s composition patent through 2030 and its formulation patent through 2038, securing exclusive rights for Acadia’s main Parkinson’s disease psychosis treatment.
Total revenues for the first half of 2025 were $508.9 million, up 14% year-over-year. NUPLAZID net sales rose 23% in Q1 2025 and 7% in Q2 2025, while DAYBUE sales increased 11% in Q1 2025 and 14% in Q2 2025, highlighting sustainable commercial momentum.
DAYBUE achieved a record 987 unique patient shipments in Q2 2025 following an expansion of the field force, showing strong adoption in Rett syndrome therapy.
Selling, general and administrative expenses increased 14% year-over-year to $133.5 million in Q2 2025, which led to net income dropping to $26.7 million from $33.4 million and signals pressure on profit margins.
NUPLAZID’s composition-of-matter patent expires in 2030, making Acadia vulnerable to generic competition and potential revenue declines afterwards.
Topline results from the Phase 3 COMPASS PWS study of ACP-101, set to be released in early Q4 2025, represent a key event that could negatively affect the stock if the results are disappointing.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
ACAD Financial Performance
Revenues and expenses
ACAD Earnings Performance
Company profitability
ACAD News
AllArticlesVideos
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
Business Wire1 week ago
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Benzinga2 weeks ago
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
Investors Business Daily2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals (ACAD) has a market cap of $3.4B as of October 11, 2025.
What is the P/E ratio for ACADIA Pharmaceuticals stock?
The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 15.13 as of October 11, 2025.
Does ACADIA Pharmaceuticals stock pay dividends?
No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of October 11, 2025.
When is the next ACADIA Pharmaceuticals dividend payment date?
ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.
What is the beta indicator for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.